Item 8.01. Other Events.

On August 15, 2022, Halozyme Therapeutics, Inc. (the "Company") issued a press release announcing that it proposes to offer, subject to market conditions and other factors, $500.0 million aggregate principal amount of convertible senior notes due 2028 (the "Convertible Notes"). The Company expects to grant to the initial purchasers an option to purchase up to an additional $75.0 million aggregate principal amount of Convertible Notes. A copy of the press release is attached hereto as Exhibit 99.1 and incorporated herein by reference.

Item 9.01. Financial Statements and Exhibits.



(d) Exhibits.

Exhibit
No.                                  Description

99.1        Press release dated August 15, 2022

104       Inline XBRL for the cover page of this Current Report on Form 8-K.

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses